The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ARCELLX INC COMMON STOCK 03940C100   86,004,430 1,047,557 SH   SOLE   1,047,557 0 0
KYMERA THERAPEUTICS INC COM 501575104   25,864,969 457,059 SH   SOLE   457,059 0 0
RAPT THERAPEUTICS INC COM NEW 75382E109   320,750 12,437 SH   SOLE   12,437 0 0
RALLYBIO CORP COM 75120L100   377,339 754,678 SH   SOLE   754,678 0 0
SEER INC COM CL A 81578P106   1,804,189 816,375 SH   SOLE   816,375 0 0
SUTRO BIOPHARMA INC COM 869367102   153,125 175,000 SH   SOLE   175,000 0 0
XILIO THERAPEUTICS INC COM 98422T100   595,559 667,742 SH   SOLE   667,742 0 0